|
Rifampicin
|
<4 years old
|
>4 years old
|
% difference
|
|---|
|
Number of patients enrolled
|
64
|
36
| |
|
Body Weight (median kg - range)
|
9.0 (4.0–15.0)
|
19.0 (13.5–43.0)
| |
|
Age (median months - range)
|
12 (2–48)
|
96 (48–180)
| |
|
Dosage (mean - % CV)
|
9.38 (12.8)
|
10.2 (9.04)
|
p-value: 0.0002a
|
|
CMAX (ug/mL)
|
4.9
|
5.96
|
−17.8
|
|
TMAX (hr)
|
2
|
3
|
−33.3
|
|
CL/F (L/hr)
|
4.66
|
7.86
|
−40.7
|
|
CL/F/BW (L/hr/kg)
|
0.52
|
0.41
|
26.8
|
|
V/F (L)
|
15.6
|
25.5
|
−38.9
|
|
V/F/BW (L/kg)
|
1.73
|
1.34
|
29.1
|
|
T1/2 (hr)
|
2.31
|
2.25
|
2.67
|
|
AUC0-∞ (hr × ug/mL)
|
21.5
|
25.4
|
−15.7
|
|
AUC0-∞/dosage (hr × ug/mL/(mg/kg))
|
2.36
|
2.6
|
−9.23
|
|
T > MIC (hr)
|
6.89
|
6.66
|
3.45
|
|
T > MIC/24 h (%)
|
28.7
|
27.8
|
3.39
|
|
AUC0–24 h > MIC (hr × ug/mL)
|
11.7
|
14.7
|
−20.1
|
- Apart for dosage with mean and % CV, all values are reported as median (range) or as median estimates for pharmacokinetic parameters. C
MAX
maximum observed plasma concentration after oral administration, T
MAX
observed time to reach CMAX, CL/F oral elimination clearance, CL/F/BW elimination clearance corrected by the median body weight, V/F apparent volume of distribution, V/F/BW apparent volume of distribution corrected by the median body weight, T
1/2
terminal elimination half-life, AUC
0-∞
predicted area under the plasma concentration-time curve after the last dose from zero time to infinity, T > MIC time above the minimum inhibitory concentration, T > MIC/24 h percentage of the time above the minimum inhibitory concentration over the 24 h dose interval, AUC > MIC observed area under the plasma concentration-time curve above the minimum inhibitory concentration. % difference is calculated with the > 4 years group used as the reference. aMann–Whitney T-test
